Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $49

Benzinga Newsdesk www.benzinga.com Positive 73.1%

Neg 0% Neu 0% Pos 73.1%

Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $48 to $49.